INTERVIEW WITH KENNETH PIENTA
The Biology of Prostate Cancer

INTERVIEW WITH JOAQUIN MATEO
Integrating PARP inhibitors into the Standard of Care for Prostate Cancer - Joaquin Mateo

INTERVIEW WITH SCOTT TAGAWA
Antibody-drug Conjugates for Metastatic Urothelial Carcinoma & 177Lu-PSMA-617 for Progressive mCRPC

INTERVIEW WITH JUNE CHAN
"Eat, Move, Sleep"

Videos
State-of-the-industry video lectures by leading urology experts
Featured Videos

#ASCO14 - Association of higher institutional volume with improved overall survival in clinical stage III testicular cancer: Results from the National Cancer Data Base (1998-2011) - Session Highlights

CHICAGO, IL USA (UroToday.com) - Advances in treatment have improved survival outcomes among men with metastatic testicular germ cell tumors (TGCTs). These advances include the use of cisplatin-based combination chemotherapy, and retroperitoneal lymph node dissection (RPLND) for persistent retroperitoneal masses after chemotherapy. Whether these treatments have truly been adopted and implemented broadly throughout the US has not been documented. Additionally, whether variability in experience with these and other treatments impacts patient outcomes is unknown. The investigators hypothesized that there would be an association between survival and hospital facility volume among men with stage III metastatic TGCT treated at high- or low-volume centers.

asco xThey used the National Cancer Data Base (NCDB) to determine whether survival among men with clinical stage III testicular germ cell tumors varied by volume of the center in which they were treated. They identified all men diagnosed with clinical stage III TGCT between 1998 and 2011 within the database. They included only men who were clinical stage III at presentation, and who were treated with chemotherapy, with the intent to assure that patients were treated in a similar way and could be expected to have similar survival outcomes. They defined “hospital volume” by the number of TGCTs diagnosed at each institution, each year, and created four groups by age of diagnosis. They then used Kaplan-Meier and Cox regression to evaluate the relationship between overall survival and hospital volume.

This study included 79 119 patients diagnosed with NGCT overall, but focused the analyses on 8 205 men who were diagnosed with clinical stage III disease. The median age at the time of diagnosis was 32, and the median length of follow-up was 5.7 years. The investigators determined that patients were most frequently seen in “comprehensive” hospitals (47.3% of men), followed by academic hospitals (10.0%), and least frequently in community settings (10.0%). In total, 1 295 men underwent RPLND (15.8% of patients) after chemotherapy.

In terms of the centers where these patients were treated, the number of cases of NGCT diagnosed varied extensively by site. The median number of NGCT cancers seen in a given institution was 8, but this ranged from 1-115 cases. Almost 25% of patients died during the study (1 225 patients, 24.8%). Overall survival at 5-years varied by hospital volume, at 74.3% in a low-volume center and 86.1% in a high-volume center. The authors note that the “greatest disparity for risk of death was recorded between the highest and lowest volume centers (HR: 0.85, p=0.003).”

In this retrospective analysis of the NCDB, overall survival among men with clinical stage III NGCT appeared to be longer when men were treated at high-volume centers as compared to treatment at low-volume centers. Although hypothesis generating, it is difficult to truly rely completely on this data as the authors did not explicitly state whether potentially critical covariates of interest (age, education status, socioeconomic status, to name a few) were (or could be) included in the analysis. It does raise the important point that differing levels of experience among providers and treatment teams, as well as resource availability, may affect patient outcomes in a very real way.

Presented by Claudio Jeldres, MD, MSc at the American Society of Clinical Oncology (ASCO) 50th Annual Meeting - May 30 - June 3, 2014 - Chicago, Illinois USA

Fred Hutchinson Cancer Research Center, Seattle, WA USA

Written by Alicia K. Morgans, MD, assistant professor of medicine and medical oncologist at Vanderbilt-Ingram Cancer Center, and medical writer for UroToday.com

 

Conference Coverage
 
Recent data from conferences worldwide
  • 2019 Annual Meeting / December 4-6 / Washington, DC
  • 2019 Annual Congress / October 17 - October 20 / Athens, Greece
  • 2019 Annual Meeting / October 3 - October 5 / Aarhus, Denmark
  • 2019 Annual Congress / September 27 - October 1 / Barcelona, Spain
  • 2019 Biennial Meeting / August 29-31 / Basel, Switzerland
  • 2019 Think Tank / August 8-10 / Washington, DC
  • 2019 Annual Meeting / May 31 - June 6 / Chicago, IL
  • 2019 Annual Meeting / May 3-6 / Chicago, IL
Journals
Publications focusing on urologic cancer treatments through original manuscripts
Calendar
Upcoming educational events
January 17-19, 2020 /
ESOU 2020
February 24-27, 2020 /
2nd Nuclear Receptors Conference
February 25-29, 2020 /
SUFU 2020 Winter Meeting